Urological complications of COVID-19: a systematic review

Int Braz J Urol. 2023 Jan-Feb;49(1):24-40. doi: 10.1590/S1677-5538.IBJU.2022.0281.

Abstract

Purpose: COVID-19 continues to be an urgent World issue. Receptors of angiotensin converting enzyme 2 (ACE2), gateway of SARS-CoV-2, are present in the lungs, bladder, prostate, and testicles. Therefore, these organs face high risk of damage caused by the virus and this mechanism may explain non-respiratory symptoms of the disease.

Materials and methods: This systematic review, guided by the PRIMSA statement, was proposed to elucidate possible urological complications of COVID-19. Searches were carried out in Medline (PubMed), Cochrane (CENTRAL), Embase, MedRxiv and LILACS. Bias analysis was made using the specific Newcastle-Ottawa Scale for each study design.

Results: Search was carried out until April 2022, and 8,477 articles were identified. Forty-nine of them were included in this systematic review. There is evidence that lower urinary tract symptoms and acute scrotum may be signs of COVID-19 in men, although in a small proportion. Also, the disease may have a transitory impact on male fertility, evidenced by several alterations in sperm counts. However, it must be clarified whether this impact is transitory, or may last for longer periods. Several patients showed reduction of total value of testosterone. Two authors linked low levels of testosterone with worse outcomes of COVID-19, suggesting that the hormone may be used as an early biomarker of the severity of the disease. Moreover, it is extremely unlikely that SARS-CoV-2 is transmitted by semen.

Conclusion: This systematic review identified possible repercussions of COVID-19 in the urinary as well as in the male reproductive system.

Keywords: COVID-19; Infertility; Testosterone.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • COVID-19* / complications
  • Humans
  • Male
  • SARS-CoV-2
  • Semen
  • Testosterone

Substances

  • Testosterone